DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Oprelvekin is an investigational drug.
There have been 4 clinical trials for Oprelvekin. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2008.
The most common disease conditions in clinical trials are Von Willebrand Diseases, Thrombocytopenia, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, University of Pittsburgh, and University of North Carolina.
Recent Clinical Trials for Oprelvekin
|Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia||Pfizer||Phase 2|
|IL-11 in Adults With Von Willebrand Disease Undergoing Surgery||University of North Carolina||Phase 2|
|IL-11 in Adults With Von Willebrand Disease Undergoing Surgery||Wyeth is now a wholly owned subsidiary of Pfizer||Phase 2|